| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Immune-correlates analysis of an HIV-1 vaccine efficacy trial.
|
N Engl J Med
|
2012
|
12.98
|
|
2
|
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.
|
J Infect Dis
|
2012
|
2.89
|
|
3
|
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.
|
AIDS Res Hum Retroviruses
|
2012
|
1.94
|
|
4
|
Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines.
|
Sci Transl Med
|
2014
|
1.87
|
|
5
|
Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial.
|
PLoS One
|
2013
|
1.65
|
|
6
|
Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.
|
J Infect Dis
|
2012
|
1.65
|
|
7
|
Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts.
|
Toxicol Sci
|
2006
|
1.22
|
|
8
|
Toxicological safety evaluation of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar despite differing plasmid backbones or gene-inserts.
|
Toxicol Sci
|
2006
|
1.02
|
|
9
|
Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer's construct, or gene inserts.
|
J Immunotoxicol
|
2008
|
1.01
|
|
10
|
HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial.
|
Immunogenetics
|
2014
|
0.90
|
|
11
|
Comparison of symptoms of influenza A with abacavir-associated hypersensitivity reaction.
|
Int J STD AIDS
|
2003
|
0.81
|